Recent advancements in ultrasound technology have introduced non-invasive treatments for liver cancer, notably through a technique called histotripsy. This method employs focused ultrasound waves to mechanically disrupt and liquefy tumor tissues without the need for surgical incisions. The U.S. Food and Drug Administration approved the first histotripsy platform, Edison™, marking a significant milestone in liver cancer treatment.
Medical institutions nationwide are adopting histotripsy. The Cleveland Clinic has successfully treated patients with liver tumors using this technology, with procedures typically lasting up to an hour. Similarly, the University of Chicago Medicine was among the first in Illinois to offer histotripsy, participating in clinical trials that contributed to its FDA approval. These developments underscore the potential of histotripsy to transform liver cancer treatment by offering a precise, non-invasive alternative to traditional surgical methods
